Loading
Invasive micropapillary carcinoma is a rare type of breast cancer in which small clusters of cells float inside-out in empty spaces. It spreads to the lymph nodes far more often than ordinary breast cancer of the same size, but once that is allowed for its survival is similar, and it is treated by receptor status like other breast cancer, usually hormone-driven.
The WHO classification defines invasive micropapillary carcinoma by morule-like clusters of cells without fibrovascular cores lying in clear stromal spaces, with reversed polarity shown by the inside-out staining of epithelial membrane antigen and sialyl Lewis X (Tan 2020; Archives of Pathology 2016). It is a variant of luminal B breast cancer, hormone-receptor positive with HER2 positivity in a proportion, with frequent lymphovascular invasion and nodal metastasis; molecular studies show distinct profiles supporting its status as an entity but no single genomic aberration explaining its morphology (Archives of Pathology 2016). Laboratory work using MCF7 spheroids modelled the chemoresistance described in the tumour through HIF-1-driven P-glycoprotein expression (BMC Cancer 2012).
How it differs from its parent: its nodal spread is out of proportion to its size, so imaging of the axilla and node surgery matter more; mixed tumours (micropapillary with no special type) are common and the threshold for calling a tumour micropapillary is not agreed.
How common: no reliable share was found in the sources read.
Treatment: by receptor status on the parent's pages, most often as HR-positive breast cancer with endocrine therapy, and with HER2-directed therapy when HER2-positive; there is no trial in the type.
Rare in its pure form; the criteria separating pure from mixed micropapillary carcinoma remain imprecise, so published shares vary (Archives of Pathology 2016). No population figure is given in the sources read.
Most cancers start in the ducts and drain first to the axillary nodes, which is why the armpit is checked and a sentinel node is sampled.
Same organ: Triple-negative breast cancer (TNBC), Breast cancer (all types), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Male breast cancer, Ductal carcinoma in situ (DCIS), High-risk early HR-positive breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors, HER2-low and HER2-ultralow metastatic breast cancer, Early HER2-positive breast cancer, HER2-positive breast cancer with brain metastases, Early triple-negative breast cancer, Metastatic triple-negative breast cancer, Basal-like 1 triple-negative breast cancer (BL1), Basal-like 2 triple-negative breast cancer (BL2), Mesenchymal triple-negative breast cancer (M), Mesenchymal stem-like triple-negative breast cancer (MSL), Luminal androgen receptor triple-negative breast cancer (LAR), Immunomodulatory triple-negative breast cancer (IM), Metaplastic breast carcinoma, Carcinoma with medullary pattern (medullary breast cancer), Adenoid cystic carcinoma of the breast, Apocrine carcinoma of the breast, Secretory carcinoma of the breast, BRCA-associated triple-negative breast cancer, Inflammatory breast cancer, Paget disease of the nipple, Phyllodes tumour of the breast, Invasive lobular carcinoma of the breast, Invasive breast carcinoma of no special type (invasive ductal carcinoma), Tubular carcinoma of the breast, Mucinous carcinoma of the breast, Papillary carcinomas of the breast (encapsulated, solid and invasive papillary), Invasive cribriform carcinoma of the breast, Invasive breast carcinoma with medullary pattern (medullary carcinoma), Neuroendocrine neoplasms of the breast, Lobular carcinoma in situ (LCIS)
Treated by receptor status on the parent's pages, with careful axillary staging.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this cancer: (TITLE:"Invasive micropapillary carcinoma of the breast" OR ABSTRACT:"Invasive micropapillary carcinoma of the breast" OR TITLE:"Invasive micropapillary carcinoma" OR ABSTRACT:"Invasive micropapillary carcinoma" OR TITLE:"IMPC" OR ABSTRACT:"IMPC" OR TITLE:"Micropapillary breast cancer" OR ABSTRACT:"Micropapillary breast cancer") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Invasive micropapillary carcinoma of the breast, not a curated reading list.
No targets or pathways are linked to this cancer yet. Browse the gene hub →
Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Newly diagnosed? Read the first 60 days with Invasive micropapillary carcinoma of the breast, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.